Thermo Fisher Scientific (NYSE:TMO) Issues Earnings Results

Thermo Fisher Scientific (NYSE:TMO) issued its quarterly earnings data on Wednesday. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $0.28, FiscalAI reports. The business had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the prior year, the firm earned $5.79 EPS.

Here are the key takeaways from Thermo Fisher Scientific’s conference call:

• Thermo Fisher raised its 2026 outlook, increasing revenue guidance to $47.7 billion–$48.2 billion, organic growth guidance to 4%, adjusted EPS guidance to $25.13–$25.43, and free cash flow guidance to $7.0 billion–$7.5 billion.
• Third-quarter performance exceeded expectations, with revenue up 9% to $12.14 billion, organic growth of 6%, adjusted EPS up 15% to $6.68, and adjusted operating margin expanding 120 basis points to 24.5%. Growth was led by Pharma Services, clinical research, electron microscopy, and improving biotech demand.
• Management reported continued strengthening in pharma and biotech customer activity, including low-to-mid/high-single-digit growth across key areas, improving biotech funding and confidence, and strong demand for clinical research, bioproduction, and semiconductor-related electron microscopy.
• The quarter benefited from approximately $60 million of net tariff-refund recovery, contributing $0.15 to adjusted EPS, although the company reinvested part of the proceeds in AI deployment, Pharma Services capacity, and employee investments. The refund benefit is largely one-time, while fourth-quarter organic growth guidance remains at 4% after some Pharma Services activity shifted into the third quarter.
• Thermo Fisher highlighted expanding AI capabilities across instruments and services, including AI-enabled cryo-electron microscopy workflows and a clinical research assistant, while the Clario acquisition and bioproduction investments are reportedly generating strong customer adoption and potential revenue synergies.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $687.72 on Wednesday. The business’s 50 day moving average price is $640.60 and its 200-day moving average price is $551.25. Thermo Fisher Scientific has a fifty-two week low of $435.27 and a fifty-two week high of $704.00. The company has a market cap of $254.28 billion, a P/E ratio of 36.99, a P/E/G ratio of 2.83 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Michael Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,768 shares of company stock valued at $44,122,820 in the last three months. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TMO. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. BMO Capital Markets cut shares of Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. Royal Bank Of Canada set a $740.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, October 15th. Finally, TD Cowen upped their target price on shares of Thermo Fisher Scientific from $675.00 to $760.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $654.05.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.